Treatment of intrabony periodontal defects using rhFGF-2 in combination with deproteinized bovine bone mineral or rhFGF-2 alone: A 6-month randomized controlled trial.

ABSTRACT:

Aim

To evaluate the use of recombinant human fibroblast growth factor (rhFGF)-2 in combination with deproteinized bovine bone mineral (DBBM) compared with rhFGF-2 alone, in the treatment of intrabony periodontal defects.

Materials and methods

Patients with periodontitis who had received initial periodontal therapy and had intrabony defects of ≥ 3 mm in depth were enrolled. Sites were randomly assigned to receive a commercial formulation of 0.3% rhFGF-2 + DBBM (test) or rhFGF-2 alone (control). Clinical parameters and a patient-reported outcome measure (PROM) were evaluated at baseline and at 3 and 6 months postoperatively.

Results

Twenty-two sites in each group were evaluated. A significant improvement in clinical attachment level (CAL) from baseline was observed in b

SUBMITTER: Saito A 

PROVIDER: S-EPMC6899590 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature